{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:49:30Z","timestamp":1793148570689,"version":"4.5.0"},"reference-count":114,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,11,17]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:p>This expert group consensus statement emphasises the need for standardising the definition of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis being of paramount importance in ensuring appropriate initial management. Equally, case-by-case decisions on monitoring and management are essential, given the varying presentations of F-ILDs and the varying rates of progression. The value of diagnostic tests in risk stratification at presentation and, separately, the importance of a logical monitoring strategy, tailored to manage the risk of progression, are also stressed. The term \u201cprogressive pulmonary fibrosis\u201d (PPF) exactly describes the entity that clinicians often face in practice. The importance of using antifibrotic therapy early in PPF (once initial management has failed to prevent progression) is increasingly supported by evidence. Artificial intelligence software for high-resolution computed tomography analysis, although an exciting tool for the future, awaits validation. Guidance is provided on pulmonary rehabilitation, oxygen and the use of non-invasive ventilation focused specifically on the needs of ILD patients with progressive disease. PPF should be differentiated from acute deterioration due to drug-induced lung toxicity or other forms of acute exacerbations. Referral criteria for a lung transplant are discussed and applied to patient needs in severe diseases where transplantation is not realistic, either due to access limitations or transplantation contraindications. In conclusion, expert group consensus guidance is provided on the diagnosis, treatment and monitoring of F-ILDs with specific focus on the recognition of PPF and the management of pulmonary fibrosis progressing despite initial management.<\/jats:p>","DOI":"10.1183\/13993003.03187-2021","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T11:35:14Z","timestamp":1671017714000},"page":"2103187","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":258,"title":["Progressive pulmonary fibrosis: an expert group consensus statement"],"prefix":"10.1183","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7955-2147","authenticated-orcid":false,"given":"Sujeet K.","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonye","family":"Danoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Renzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarir","family":"Udwadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanabha","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Currow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Devraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavin","family":"Jankharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Kulshrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ravaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Quadrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajam","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-9163","authenticated-orcid":false,"given":"Sahajal","family":"Dhooria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-1467","authenticated-orcid":false,"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol U.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"2024102103102000000_61.3.2103187.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00692-2018"},{"key":"2024102103102000000_61.3.2103187.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2024102103102000000_61.3.2103187.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2024102103102000000_61.3.2103187.4","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1159\/000509556","article-title":"Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers","volume":"99","author":"Faverio","year":"2020","journal-title":"Respiration"},{"key":"2024102103102000000_61.3.2103187.5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2024102103102000000_61.3.2103187.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02718-2020"},{"key":"2024102103102000000_61.3.2103187.7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/rheumatology\/kex077","article-title":"Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study","volume":"57","author":"Reiseter","year":"2018","journal-title":"Rheumatology"},{"key":"2024102103102000000_61.3.2103187.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00221-2021"},{"key":"2024102103102000000_61.3.2103187.9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.39971","article-title":"Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease","volume":"69","author":"Zamora-Legoff","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024102103102000000_61.3.2103187.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2005230"},{"key":"2024102103102000000_61.3.2103187.11","unstructured":"American Lung Association . Interstitial lung disease. 2021. www.lung.org\/lung-health-diseases\/lung-disease-lookup\/interstitial-lung-disease Date last accessed: 25 November 2022."},{"key":"2024102103102000000_61.3.2103187.12","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-1296-3"},{"key":"2024102103102000000_61.3.2103187.13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12890-016-0245-x","article-title":"From \u201ctraction bronchiectasis\u201d to honeycombing in idiopathic pulmonary fibrosis: a spectrum of bronchiolar remodeling also in radiology?","volume":"16","author":"Piciucchi","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2024102103102000000_61.3.2103187.14","doi-asserted-by":"crossref","first-page":"e0191938","DOI":"10.1371\/journal.pone.0191938","article-title":"Spectrum of interstitial lung diseases at a tertiary center in a developing country: a study of 803 subjects","volume":"13","author":"Dhooria","year":"2018","journal-title":"PLoS One"},{"key":"2024102103102000000_61.3.2103187.15","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0109-2019"},{"key":"2024102103102000000_61.3.2103187.16","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.4103\/lungindia.lungindia_818_20","article-title":"Post-COVID lung fibrosis: the tsunami that will follow the earthquake","volume":"38","author":"Udwadia","year":"2021","journal-title":"Lung India"},{"key":"2024102103102000000_61.3.2103187.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00131912"},{"key":"2024102103102000000_61.3.2103187.18","doi-asserted-by":"crossref","first-page":"2101396","DOI":"10.1183\/13993003.01396-2021","article-title":"Lung function trajectory in progressive fibrosing interstitial lung disease","volume":"59","author":"Oldham","year":"2021","journal-title":"Eur Respir J"},{"key":"2024102103102000000_61.3.2103187.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2784"},{"key":"2024102103102000000_61.3.2103187.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01681-2019"},{"key":"2024102103102000000_61.3.2103187.21","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210035"},{"key":"2024102103102000000_61.3.2103187.22","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1164\/rccm.201902-0360OC","article-title":"Rare protein-altering telomere-related gene variants in patients with chronic hypersensitivity pneumonitis","volume":"200","author":"Ley","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103102000000_61.3.2103187.23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40744-021-00362-4","article-title":"A closer look at the role of anti-CCP antibodies in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and bronchiectasis","volume":"8","author":"Khan","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2024102103102000000_61.3.2103187.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200863"},{"key":"2024102103102000000_61.3.2103187.25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00357-2015"},{"key":"2024102103102000000_61.3.2103187.26","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024102103102000000_61.3.2103187.27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00296-017-3916-x","article-title":"Interstitial lung disease in systemic sclerosis: data from the Spanish Scleroderma Study Group","volume":"38","author":"S\u00e1nchez-Cano","year":"2018","journal-title":"Rheumatol Int"},{"key":"2024102103102000000_61.3.2103187.28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ebiom.2019.10.050","article-title":"Endotype\u2013phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease","volume":"50","author":"Hoffmann-Vold","year":"2019","journal-title":"EBioMedicine"},{"key":"2024102103102000000_61.3.2103187.29","doi-asserted-by":"crossref","first-page":"e0181692","DOI":"10.1371\/journal.pone.0181692","article-title":"Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Le Gouellec","year":"2017","journal-title":"PLoS One"},{"key":"2024102103102000000_61.3.2103187.30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s43055-020-00220-3","article-title":"Systemic sclerosis: correlation between lung abnormalities on high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs)","volume":"51","author":"Ibrahim","year":"2020","journal-title":"Egypt J Radiol Nucl Med"},{"key":"2024102103102000000_61.3.2103187.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200706-877OC"},{"key":"2024102103102000000_61.3.2103187.32","first-page":"S53","article-title":"Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis","volume":"29","author":"Deuschle","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2024102103102000000_61.3.2103187.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2024102103102000000_61.3.2103187.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2024102103102000000_61.3.2103187.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102103102000000_61.3.2103187.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103690"},{"key":"2024102103102000000_61.3.2103187.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2024102103102000000_61.3.2103187.38","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2024102103102000000_61.3.2103187.39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/jcm6050051","article-title":"Role of autoantibodies in the diagnosis of connective-tissue disease ILD (CTD-ILD) and interstitial pneumonia with autoimmune features (IPAF)","volume":"6","author":"Jee","year":"2017","journal-title":"J Clin Med"},{"key":"2024102103102000000_61.3.2103187.40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00276-2021"},{"key":"2024102103102000000_61.3.2103187.41","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1513\/AnnalsATS.202005-420OC","article-title":"Bronchoalveolar lavage lymphocytes in the diagnosis of hypersensitivity pneumonitis among patients with interstitial lung disease","volume":"17","author":"Patolia","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2024102103102000000_61.3.2103187.42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-2032ST"},{"key":"2024102103102000000_61.3.2103187.43","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01633-2016"},{"key":"2024102103102000000_61.3.2103187.44","unstructured":"King TE , Raj R . Role of lung biopsy in the diagnosis of interstitial lung disease \u2013 UpToDate. 2022. www.uptodate.com\/contents\/role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease Date last accessed: 25 November 2022."},{"key":"2024102103102000000_61.3.2103187.45","first-page":"75","article-title":"Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCISTM)","volume":"35","author":"Distler","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2024102103102000000_61.3.2103187.46","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034505"},{"key":"2024102103102000000_61.3.2103187.47","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00155108"},{"key":"2024102103102000000_61.3.2103187.48","doi-asserted-by":"publisher","DOI":"10.1097\/RTI.0b013e3182a21969"},{"key":"2024102103102000000_61.3.2103187.49","first-page":"e20200096","article-title":"Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases","volume":"47","author":"Torres","year":"2021","journal-title":"J Bras Pneumol"},{"key":"2024102103102000000_61.3.2103187.50","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.211.2.r99ma01555"},{"key":"2024102103102000000_61.3.2103187.51","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.182.2.1732946"},{"key":"2024102103102000000_61.3.2103187.52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clinimag.2019.07.003","article-title":"Progression of probable UIP and UIP on HRCT","volume":"58","author":"Salvatore","year":"2019","journal-title":"Clin Imaging"},{"key":"2024102103102000000_61.3.2103187.53","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092309"},{"key":"2024102103102000000_61.3.2103187.54","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203843"},{"key":"2024102103102000000_61.3.2103187.55","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0076-2018"},{"key":"2024102103102000000_61.3.2103187.56","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0017-2021"},{"key":"2024102103102000000_61.3.2103187.57","first-page":"E68","article-title":"Lung transplantation in idiopathic pulmonary fibrosis","volume":"6","author":"Laporta Hernandez","year":"2018","journal-title":"Med Sci"},{"key":"2024102103102000000_61.3.2103187.58","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation","volume":"40","author":"Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2024102103102000000_61.3.2103187.59","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1038\/s41598-018-23073-3","article-title":"Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"key":"2024102103102000000_61.3.2103187.60","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2111053"},{"key":"2024102103102000000_61.3.2103187.61","doi-asserted-by":"publisher","DOI":"10.1097\/RTI.0b013e3181e35823"},{"key":"2024102103102000000_61.3.2103187.62","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00131813"},{"key":"2024102103102000000_61.3.2103187.63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12890-015-0161-5","article-title":"Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis","volume":"15","author":"Reichmann","year":"2015","journal-title":"BMC Pulm Med"},{"key":"2024102103102000000_61.3.2103187.64","first-page":"P2353","article-title":"The relation of six-minute walk test and lung function in interstitial lung disease","volume":"42","author":"Rosa","year":"2013","journal-title":"Eur Respir J"},{"key":"2024102103102000000_61.3.2103187.65","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202640"},{"key":"2024102103102000000_61.3.2103187.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.03.037"},{"key":"2024102103102000000_61.3.2103187.67","first-page":"116","article-title":"State of the art in the diagnosis and management of interstitial lung disease","volume":"88","author":"Buzan","year":"2015","journal-title":"Clujul Med"},{"key":"2024102103102000000_61.3.2103187.68","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102103102000000_61.3.2103187.69","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/03007995.2020.1860920","article-title":"Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union","volume":"37","author":"Takizawa","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2024102103102000000_61.3.2103187.70","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2024102103102000000_61.3.2103187.71","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(20)30036-9"},{"key":"2024102103102000000_61.3.2103187.72","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01592-2016"},{"key":"2024102103102000000_61.3.2103187.73","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0840OC"},{"key":"2024102103102000000_61.3.2103187.74","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102103102000000_61.3.2103187.75","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2024102103102000000_61.3.2103187.76","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2024102103102000000_61.3.2103187.77","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/17476348.2021.2001331","article-title":"The emerging role of mycophenolate mofetil in interstitial lung diseases","volume":"15","author":"Brown","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"2024102103102000000_61.3.2103187.78","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103102000000_61.3.2103187.79","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000289"},{"key":"2024102103102000000_61.3.2103187.80","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151322"},{"key":"2024102103102000000_61.3.2103187.81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103102000000_61.3.2103187.82","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(21)00173-9","article-title":"Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed","volume":"9","author":"Wells","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103102000000_61.3.2103187.83","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12931-021-01668-1","article-title":"Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases","volume":"22","author":"Cottin","year":"2021","journal-title":"Respir Res"},{"key":"2024102103102000000_61.3.2103187.84","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00198013"},{"key":"2024102103102000000_61.3.2103187.85","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/PROM.S144425","article-title":"Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives","volume":"9","author":"Graney","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"2024102103102000000_61.3.2103187.86","doi-asserted-by":"publisher","DOI":"10.1586\/ers.10.32"},{"key":"2024102103102000000_61.3.2103187.87","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2147\/DHPS.S224007","article-title":"Updated evaluation of the safety, efficacy and tolerability of pirfenidone in the treatment of idiopathic pulmonary fibrosis","volume":"12","author":"Gulati","year":"2020","journal-title":"Drug Healthc Patient Saf"},{"key":"2024102103102000000_61.3.2103187.88","doi-asserted-by":"crossref","first-page":"12062","DOI":"10.1038\/s41598-019-48593-4","article-title":"Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis","volume":"9","author":"Kato","year":"2019","journal-title":"Sci Rep"},{"key":"2024102103102000000_61.3.2103187.89","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40264-020-00978-5","article-title":"Anticoagulant use and bleeding risk in central European patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotic therapy: real-world data from EMPIRE","volume":"43","author":"Kolonics-Farkas","year":"2020","journal-title":"Drug Saf"},{"key":"2024102103102000000_61.3.2103187.90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/ijmr.IJMR_90_20","article-title":"Antifibrotic drugs for idiopathic pulmonary fibrosis: what we should know?","volume":"152","author":"Hadda","year":"2020","journal-title":"Indian J Med Res"},{"key":"2024102103102000000_61.3.2103187.91","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7150\/ijms.11579","article-title":"Role and new insights of pirfenidone in fibrotic diseases","volume":"12","author":"Lopez-de la Mora","year":"2015","journal-title":"Int J Med Sci"},{"key":"2024102103102000000_61.3.2103187.92","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-571OC"},{"key":"2024102103102000000_61.3.2103187.93","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201701-0091OC"},{"key":"2024102103102000000_61.3.2103187.94","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0398-4"},{"key":"2024102103102000000_61.3.2103187.95","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200508-1211ST"},{"key":"2024102103102000000_61.3.2103187.96","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.5.1951"},{"key":"2024102103102000000_61.3.2103187.97","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.101691"},{"key":"2024102103102000000_61.3.2103187.98","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001814"},{"key":"2024102103102000000_61.3.2103187.99","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000464332","article-title":"Idiopathic pulmonary fibrosis in Switzerland: diagnosis and treatment","volume":"93","author":"Funke-Chambour","year":"2017","journal-title":"Respiration"},{"key":"2024102103102000000_61.3.2103187.100","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-206865"},{"key":"2024102103102000000_61.3.2103187.101","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000455879","article-title":"Long-term oxygen therapy: comparison of the German and British Guidelines","volume":"93","author":"Magnet","year":"2017","journal-title":"Respiration"},{"key":"2024102103102000000_61.3.2103187.102","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/resp.12678","article-title":"Clinical practice guideline on adult domiciliary oxygen therapy: executive summary from the Thoracic Society of Australia and New Zealand","volume":"21","author":"McDonald","year":"2016","journal-title":"Respirology"},{"key":"2024102103102000000_61.3.2103187.103","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00118-2019"},{"key":"2024102103102000000_61.3.2103187.104","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102103102000000_61.3.2103187.105","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61115-4"},{"key":"2024102103102000000_61.3.2103187.106","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1164\/rccm.202009-3608ST","article-title":"Home oxygen therapy for adults with chronic lung disease. An official American Thoracic Society clinical practice guideline","volume":"202","author":"Jacobs","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103102000000_61.3.2103187.107","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0100-2018"},{"key":"2024102103102000000_61.3.2103187.108","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.rmed.2009.08.001","article-title":"Effects of proportional assisted ventilation on exercise performance in idiopathic pulmonary fibrosis patients","volume":"104","author":"Moderno","year":"2010","journal-title":"Respir Med"},{"key":"2024102103102000000_61.3.2103187.109","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2014.0010"},{"key":"2024102103102000000_61.3.2103187.110","first-page":"871","article-title":"Long-term oxygen therapy","volume":"115","author":"Koczulla","year":"2018","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2024102103102000000_61.3.2103187.111","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00039003"},{"key":"2024102103102000000_61.3.2103187.112","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-211589"},{"key":"2024102103102000000_61.3.2103187.113","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2018-001749"},{"key":"2024102103102000000_61.3.2103187.114","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/10499091211018193","article-title":"Integrating palliative care assessment tools to enhance understanding of illness trajectory in post-acute care and long-term care","volume":"39","author":"Grossman","year":"2022","journal-title":"Am J Hosp Palliat Care"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.03187-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:12:09Z","timestamp":1740359529000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.03187-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":114,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,30]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1183\/13993003.03187-2021"],"URL":"https:\/\/doi.org\/10.1183\/13993003.03187-2021","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]}}}